Abstract
CURRENT emphasis in research on lysosomal storage diseases is directed towards enzyme replacement therapy (ERT) for these inherited enzyme deficiencies1–3. The rationale for ERT is based on the assumption that endocytosed enzyme would enter lysosomes and function in the degradation of accumulated substrates. However, inactivation of enzyme, immunological reactions and low cellular uptake have prevented successful application of this promising approach to therapy. Circumvention of these limitations requires the use of carriers which protect and stabilise replacement enzyme while enhancing uptake and subcellular distribution2–5. We report here the use of lipid vesicles (liposomes)6–9 as carriers for replacement enzyme in feline GM1 gangliosidosis fibroblasts which have deficient β-galactosidase (β-gal) activity and lysosomal storage of glycopeptides9–11. Our results demonstrate increased β-gal activity and corresponding catabolism of stored glycopeptides in feline GM1 gangliosidosis fibroblasts treated with liposomes containing β-gal.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
